Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03105843

Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol

The objectives of this study are to determine the sensory-mechanical responses to Eucapneic Voluntary Hyperventilation (EVH) and Mannitol in individuals with cough variant asthma (CVA) and methacholine-induced cough with normal airway sensitivity (COUGH) and compare these responses to a control group of healthy individuals without asthma or chronic cough.

We hypothesize:

1. EVH and Mannitol cause dyspnea, cough, small airway obstruction with resultant dynamic hyperinflation, gas trapping and autoPEEP in individuals with CVA and COUGH, but not healthy controls. 2. The sensory-mechanical responses to both hyperosmolar challenges (EVH and Mannitol) are comparable within groups (CVA, COUGH and healthy controls).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada

Location status: Recruiting

Location contact

M Diane Lougheed, MD MSc

PRINCIPAL_INVESTIGATOR

Taylar Wall

CONTACT

[email protected]

613-549-6666 ext. 2798

About this study

Asthma is a chronic respiratory condition characterized by eosinophilic airway inflammation. Individuals with classic asthma experience paroxysmal symptoms including cough, wheeze, shortness of breath and chest tightness. Cough variant asthma (CVA) is asthma in which chronic cough (cough lasting eight weeks or more) is the sole or predominant symptom of asthma. The pathophysiologic mechanisms which differentiate asthma, CVA, and eosinophilic bronchitis without asthma are not fully understood. We have recently identified individuals with chronic cough who cough during methacholine but have normal airway sensitivity (ie. do not have asthma or CVA) (COUGH) and may or may not have eosinophilic bronchitis. The purpose of this research is to further explore the pathophysiologic basis for cough in these conditions using two 'indirect' inhalation challenge tests: eucapneic voluntary hyperventilation (EVH) and Mannitol), which induce osmotic and/or temperature changes in airway. Specifically, this study will collect preliminary data on the sensory-mechanical responses of individuals with CVA, COUGH and healthy controls to EVH and Mannitol Challenges.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 18-65 years of age with CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used:
  • CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator);
  • Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 > 16 mg/mL).
  • Individuals aged 18-65 years of age with no history of asthma or chronic cough.

Exclusion criteria

  • an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks
  • inability to perform acceptable spirometry
  • medical contraindications to methacholine challenge testing
  • smoking history in excess of 10 pack years Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.

Treatment and study plan

Methacholine (MCh) Challenge Testing

Drug

Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.

Other names: MCh[inhalation of sequential doubling doses of MCh(0.0625-16 mg/mL)], Provocholine

Eucapneic Voluntary Hyperventilation (EVH)

Diagnostic Test

Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Mannitol Inhalation Kit

Drug

Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.

Other names: Mannitol Challenge Test

Primary outcomes

  1. Mid expiratory flows

    Time frame: Time frame of the methacholine challenge varies between individuals. At provocative dose/ventilation causing a 20% decline in FEV1 (PD20 and PC20 respectively). On average, these occur about 15-25 minutes into the challenge test

    The bronchodilating effect of a DI will be examined using responses to the challenge testing (Visit 2/3) in these subgroups by comparing the mid-expiratory flow difference between the partial (PEF) and full maximal flow-volume (MEF) loops at 40% above Residual Volume (RV) from the forced vital capacity (FVC) (PEF40 and MEF40 respectively) at provocative dose of 4.5% saline causing a 20% decline in FEV1 (PD20 (HS)) and provocative minute ventilation causing a 20% decline in FEV1 (PC20 (EVH)) with that recorded at baseline.

Secondary outcomes

  1. Respiratory System Reactance (X5)

    Time frame: After dose administration; will occur 2-5 minutes after dose

    Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.

  2. Peripheral Resistance (R5-R20)

    Time frame: After dose administration; will occur 2-5 minutes after dose

    Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.

  3. Central Airway Resistance

    Time frame: After dose administration; will occur 2-5 minutes after dose

    Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.

  4. Forced Vital Capacity (FVC)

    Time frame: After dose administration; will occur 2-5 minutes after dose

    As an index of airway closure.

  5. FEV1/FVC

    Time frame: After dose administration; will occur 2-5 minutes after dose

    As an index of airway obstruction.

Study contacts

Contact information is provided by the study sponsor or research team.

M. Diane Lougheed, MD, MSc

CONTACT

[email protected]

613-548-2348

Taylar Wall, RRT

CONTACT

[email protected]

613-549-6666 ext. 2798

Sponsors and collaborators

Lead sponsor

Dr. Diane Lougheed

Other

Registry information

Official study title

Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Mannitol in Individuals With Cough Variant Asthma and Chronic Cough

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 10, 2017
Registry last updated
Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.